Scientech Research LLC’s Editas Medicine EDIT Stock Holding History

Scientech Research LLC’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-24,353	Closed	-$30.9K	–	633
2024 Q4	$30.9K	Buy	+24,353	New	+$62.1K	0.01%	523

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Scientech Research LLC's EDIT Position: Q1 2025 in Review

Scientech Research LLC sold out of Editas Medicine (EDIT) in Q1 2025, closing a stake of 24,353 shares — an estimated $30.9K sold.

Scientech Research LLC first reported a position in EDIT in Q4 2024 and held it in 1 quarter. The position peaked at $30.9K in Q4 2024. 194 funds tracked by Wall St. Rank hold EDIT as of Q1 2025.

Scientech Research LLC reported no remaining Editas Medicine position as of Q1 2025 after selling out during the quarter.
Scientech Research LLC sold 24,353 Editas Medicine shares in Q1 2025, an estimated $30.9K.
Scientech Research LLC first reported a position in Editas Medicine in Q4 2024 and held it in 1 quarter.
Scientech Research LLC's Editas Medicine position peaked at $30.9K in Q4 2024.
194 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2025.

Based on Scientech Research LLC's 13F filing for Q1 2025, filed 15 May 2025.